STOCK TITAN
  1. Home
  2. Sec-filings
  3. PAHC
  4. [Form 4] PHIBRO ANIMAL HEALTH CORP Insider Trading Activity

Phibro Animal Health (PAHC) insider entity BFI Co. LLC sells shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Phibro Animal Health’s 10% owner BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, reported planned sales of Class A common stock under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 21, 2026, BFI sold 14,687 shares at a weighted average price of $41.6782 per share. On January 22, 2026, it sold 11,875 shares at a weighted average price of $41.9086 and 1,283 shares at a weighted average price of $42.6774, with each price reflecting multiple trades within stated ranges. The filing also shows that Jack Bendheim directly held 16,840 Class A shares as of January 21, 2026.

Positive

  • None.

Negative

  • None.
Insider BENDHEIM JACK, BFI Co., LLC
Role President and CEO | 10% Owner
Sold 27,845 shs ($1.16M)
Type Security Shares Price Value
Sale Class A Common Stock 11,875 $41.9086 $498K
Sale Class A Common Stock 1,283 $42.6774 $55K
Sale Class A Common Stock 14,687 $41.6782 $612K
holding Class A Common Stock -- -- --
Holdings After Transaction: Class A Common Stock — 16,680 shares (Indirect, See); Class A Common Stock — 16,840 shares (Direct)
Footnotes (6)
  1. F1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
  2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.11 to $42.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.
  3. F3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.53.
  5. F5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.62 to $42.77.
  6. F6. The reported securities are directly held by Jack Bendheim.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

Who reported the recent PAHC insider share sales?

The sales were reported by BFI Co., LLC, a 10% owner of Phibro Animal Health and an entity over which President and CEO Jack Bendheim exercises voting and dispositive power.

How many Phibro Animal Health (PAHC) shares did BFI Co., LLC sell and on which dates?

On January 21, 2026, BFI sold 14,687 Class A shares. On January 22, 2026, it sold 11,875 shares in one transaction and 1,283 shares in another.

At what prices were the PAHC shares sold in this Form 4?

The weighted average sale prices were $41.6782 on January 21, 2026, and $41.9086 and $42.6774 for the two January 22, 2026 transactions, each representing multiple trades within disclosed price ranges.

Was the PAHC insider selling done under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported sales were effected under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.

Did Jack Bendheim personally sell PAHC shares in this filing?

The filing attributes the reported sales to BFI Co., LLC. It separately notes that 16,840 Class A shares are directly held by Jack Bendheim, without reporting a sale of those directly held shares.

What ongoing PAHC share holdings are indicated for BFI Co., LLC and Jack Bendheim?

The filing shows BFI Co., LLC continuing to hold Phibro shares indirectly after the reported sales, and it lists 16,840 Class A shares directly held by Jack Bendheim as of January 21, 2026.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BENDHEIM JACK
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 01/21/2026 S(1) 14,687 D $41.6782(2) 29,838 I See(3)
Class A Common Stock 01/22/2026 S(1) 11,875 D $41.9086(4) 17.963 I See(3)
Class A Common Stock 01/22/2026 S(1) 1,283 D $42.6774(5) 16,680 I See(3)
Class A Common Stock 16,840 D(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
BENDHEIM JACK
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
BFI Co., LLC
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.11 to $42.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.
3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.53.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.62 to $42.77.
6. The reported securities are directly held by Jack Bendheim.
/s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim 01/22/2026
/s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC 01/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR